Cas9 Gene-Editing therapy (CureVac/CRISPR)

N/A

Report date: 2025/09/05 14:00:02

Base Information

Drug NameCas9 Gene-Editing therapy (CureVac/CRISPR)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCureVac SE
China Registration ClassN/A

Develop Information

Active CompaniesCureVac SECrispr Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A